Petrus Trust Company LTA Takes Position in USANA Health Sciences, Inc. $USNA

Key Points

• Petrus Trust Company LTA has acquired a new stake in USANA Health Sciences, purchasing 13,411 shares valued at approximately $362,000.
• USANA Health Sciences reported a net margin of 3.79% and earnings per share (EPS) of $0.74 for the last quarter, exceeding analyst expectations.
• Two analysts upgraded USANA's stock from a "hold" rating to a "buy" rating, while consensus remains a "hold" with an average price target of $36.00.

Petrus Trust Company LTA purchased a new stake in USANA Health Sciences, Inc. (NYSE:USNA - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 13,411 shares of the company's stock, valued at approximately $362,000. Petrus Trust Company LTA owned about 0.07% of USANA Health Sciences at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of USNA. Price T Rowe Associates Inc. MD increased its stake in USANA Health Sciences by 15.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,234 shares of the company's stock worth $260,000 after purchasing an additional 985 shares in the last quarter. Northern Trust Corp increased its stake in USANA Health Sciences by 16.5% during the 4th quarter. Northern Trust Corp now owns 135,937 shares of the company's stock worth $4,879,000 after purchasing an additional 19,266 shares in the last quarter. Jane Street Group LLC increased its stake in USANA Health Sciences by 330.0% during the 4th quarter. Jane Street Group LLC now owns 39,979 shares of the company's stock worth $1,435,000 after purchasing an additional 30,681 shares in the last quarter. Bank of America Corp DE increased its stake in USANA Health Sciences by 36.5% during the 4th quarter. Bank of America Corp DE now owns 19,388 shares of the company's stock worth $696,000 after purchasing an additional 5,188 shares in the last quarter. Finally, K2 Principal Fund L.P. bought a new stake in USANA Health Sciences during the 4th quarter worth approximately $359,000. 54.25% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised USANA Health Sciences from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. Two analysts have rated the stock with a Hold rating, According to MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $36.00.

USANA Health Sciences Price Performance

Shares of USNA traded down $0.30 during mid-day trading on Friday, hitting $30.56. 132,472 shares of the company's stock were exchanged, compared to its average volume of 107,758. The company has a market cap of $558.39 million, a PE ratio of 16.98, a P/E/G ratio of 0.98 and a beta of 0.64. USANA Health Sciences, Inc. has a 52 week low of $23.10 and a 52 week high of $41.83. The company has a 50-day simple moving average of $31.09 and a 200 day simple moving average of $29.52.

USANA Health Sciences (NYSE:USNA - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The company reported $0.74 earnings per share for the quarter, topping the consensus estimate of $0.54 by $0.20. The company had revenue of $235.85 million during the quarter, compared to analysts' expectations of $225.20 million. USANA Health Sciences had a net margin of 3.79% and a return on equity of 9.48%. USANA Health Sciences has set its FY 2025 guidance at 2.350-3.000 EPS. On average, analysts anticipate that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current year.

Insider Activity at USANA Health Sciences

In other news, Director Gilbert A. Fuller sold 1,058 shares of the firm's stock in a transaction that occurred on Thursday, August 7th. The shares were sold at an average price of $29.10, for a total transaction of $30,787.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider David Mulham Mulham sold 3,515 shares of the stock in a transaction that occurred on Wednesday, July 30th. The shares were sold at an average price of $30.26, for a total value of $106,363.90. Following the completion of the sale, the insider directly owned 9,260 shares of the company's stock, valued at approximately $280,207.60. The trade was a 27.51% decrease in their position. The disclosure for this sale can be found here. 0.63% of the stock is owned by company insiders.

USANA Health Sciences Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.